Phase 1/2 results from Monumental-1

Background Talquetamab is a novel first-in-class, off-the-shelf, T cell-redirecting bispecific antibody directed against the new antigen target GPRC5D. GPRC5D is a novel antigen target in myeloma that is highly expressed on malignant plasma cells and that has limited expression in normal human tissues, including hematopoietic stem cells. Talquetamab therapy produced an overall response rate (ORR) … Read more